CR11327A - Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas - Google Patents

Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas

Info

Publication number
CR11327A
CR11327A CR11327A CR11327A CR11327A CR 11327 A CR11327 A CR 11327A CR 11327 A CR11327 A CR 11327A CR 11327 A CR11327 A CR 11327A CR 11327 A CR11327 A CR 11327A
Authority
CR
Costa Rica
Prior art keywords
quinazolinadiona
preparation
derivatives
therapeutic applications
compounds
Prior art date
Application number
CR11327A
Other languages
English (en)
Inventor
Clauss Annie
Glaess Christophe
Marciniak Gilbert
Muzet Nicolas
Nave Jean-Francois
Seyer Andre
Vivet Bertrand
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CR11327A publication Critical patent/CR11327A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invencion tiene por objeto los compuestos de formula (i) en el estado de base, de hidrato, de solvato o de sus mezclas. La invencion se refiere igualmente al procedimiento de preparacion asi como a las utilizaciones en terapeutica de los compuestos de forumula (I).
CR11327A 2007-10-03 2010-03-22 Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas CR11327A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706931A FR2921926B1 (fr) 2007-10-03 2007-10-03 Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.

Publications (1)

Publication Number Publication Date
CR11327A true CR11327A (es) 2010-09-13

Family

ID=39470387

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11327A CR11327A (es) 2007-10-03 2010-03-22 Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas

Country Status (40)

Country Link
US (1) US8242126B2 (es)
EP (1) EP2205593B1 (es)
JP (1) JP5411143B2 (es)
KR (1) KR20100082345A (es)
CN (1) CN101842368B (es)
AR (1) AR070655A1 (es)
AU (1) AU2008337382B2 (es)
BR (1) BRPI0818690A2 (es)
CA (1) CA2701150C (es)
CL (1) CL2008002946A1 (es)
CO (1) CO6270227A2 (es)
CR (1) CR11327A (es)
CY (1) CY1117461T1 (es)
DK (1) DK2205593T3 (es)
DO (1) DOP2010000089A (es)
EA (1) EA018766B1 (es)
EC (1) ECSP10010058A (es)
ES (1) ES2567567T3 (es)
FR (1) FR2921926B1 (es)
GT (1) GT201000069A (es)
HN (1) HN2010000572A (es)
HR (1) HRP20160359T1 (es)
HU (1) HUE028770T2 (es)
IL (1) IL204814A0 (es)
MA (1) MA31832B1 (es)
MX (1) MX2010003495A (es)
MY (1) MY153763A (es)
NI (1) NI201000039A (es)
NZ (1) NZ584430A (es)
PA (1) PA8797701A1 (es)
PE (1) PE20090960A1 (es)
PL (1) PL2205593T3 (es)
SI (1) SI2205593T1 (es)
SV (1) SV2010003514A (es)
TN (1) TN2010000130A1 (es)
TW (1) TWI421076B (es)
UA (1) UA99485C2 (es)
UY (1) UY31376A1 (es)
WO (1) WO2009077680A1 (es)
ZA (1) ZA201002307B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8107260B2 (en) * 2007-11-15 2012-01-31 Illinois Tool Works Inc. EMI shielding and environmental seal device
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
FR2944206B1 (fr) * 2009-04-09 2012-12-28 Sanofi Aventis Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
KR101116234B1 (ko) * 2009-10-29 2014-03-06 (주)퓨쳐켐 (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
AU2011261164A1 (en) 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
CA2871237A1 (en) 2012-04-24 2013-10-31 Chugai Seiyaku Kabushiki Kaisha Benzamide derivative
US9567304B2 (en) * 2012-04-24 2017-02-14 Chugai Seiyaku Kabushiki Kaisha Quinazolinedione derivative
US9499496B2 (en) 2012-06-05 2016-11-22 University Of Kansas Inhibitors of respiratory syncytial virus
WO2015003879A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicylic derivatives
TW201605805A (zh) 2013-10-23 2016-02-16 Chugai Pharmaceutical Co Ltd 喹唑啉酮及異喹啉酮衍生物
CZ2015601A3 (cs) * 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CN107267455A (zh) * 2017-08-23 2017-10-20 安徽惠恩生物科技股份有限公司 一种嵌合抗原受体nk细胞的制备方法
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
CA2218548A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited Xanthines and their therapeutic use
JP2002308774A (ja) * 2001-04-12 2002-10-23 Nippon Zoki Pharmaceut Co Ltd Ｉｖ型ホスホジエステラーゼ選択的阻害剤
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
US20090111837A1 (en) 2005-03-01 2009-04-30 Peter Cox Use of pde7 inhibitors for the treatment of neuropathic pain
US7846664B2 (en) 2005-12-07 2010-12-07 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (CLL)

Also Published As

Publication number Publication date
TWI421076B (zh) 2014-01-01
ECSP10010058A (es) 2010-04-30
UY31376A1 (es) 2009-05-29
DOP2010000089A (es) 2010-05-15
PL2205593T3 (pl) 2016-09-30
NZ584430A (en) 2011-11-25
HUE028770T2 (en) 2016-12-28
IL204814A0 (en) 2010-11-30
TN2010000130A1 (fr) 2011-09-26
MY153763A (en) 2015-03-13
CO6270227A2 (es) 2011-04-20
GT201000069A (es) 2012-03-26
JP2010540602A (ja) 2010-12-24
MA31832B1 (fr) 2010-11-01
FR2921926A1 (fr) 2009-04-10
HRP20160359T1 (hr) 2016-05-06
NI201000039A (es) 2010-08-13
AU2008337382A1 (en) 2009-06-25
SV2010003514A (es) 2011-01-31
PE20090960A1 (es) 2009-08-10
CN101842368B (zh) 2014-03-12
WO2009077680A1 (fr) 2009-06-25
CL2008002946A1 (es) 2010-02-12
EP2205593B1 (fr) 2016-01-13
ES2567567T3 (es) 2016-04-25
CY1117461T1 (el) 2017-04-26
ZA201002307B (en) 2011-06-29
KR20100082345A (ko) 2010-07-16
CA2701150C (fr) 2016-08-16
BRPI0818690A2 (pt) 2015-04-14
CN101842368A (zh) 2010-09-22
EA018766B1 (ru) 2013-10-30
AR070655A1 (es) 2010-04-28
CA2701150A1 (fr) 2009-06-25
UA99485C2 (ru) 2012-08-27
EP2205593A1 (fr) 2010-07-14
PA8797701A1 (es) 2009-05-15
US20100298298A1 (en) 2010-11-25
EA201070424A1 (ru) 2011-04-29
SI2205593T1 (sl) 2016-05-31
AU2008337382B2 (en) 2013-11-21
JP5411143B2 (ja) 2014-02-12
FR2921926B1 (fr) 2009-12-04
MX2010003495A (es) 2010-04-21
US8242126B2 (en) 2012-08-14
HN2010000572A (es) 2013-03-11
TW200922591A (en) 2009-06-01
DK2205593T3 (en) 2016-04-18

Similar Documents

Publication Publication Date Title
CR11327A (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
UY30804A1 (es) Derivados de nicotinamida, sus sales y solvatos, composiciones farmacéuticas conteniendolas y aplicaciones
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
UY30789A1 (es) Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
UY30863A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CR8246A (es) Forma cristalina gamma-d del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que las contienen
CR11491A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
UY32325A (es) Inhibidores de ns3 proteasa del vhc
UY29518A1 (es) Derivados de alquil-, alquenil- y alquinilcarbamatos, su preparación y su aplicación en terapéutica.
UY31689A1 (es) Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica
UY29486A1 (es) Compuestos utiles en terapia
UY29690A1 (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica.
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
PE20160120A1 (es) Derivados de nucleosido 4'-fluoro-2'-metilo sustituido
ATE445593T1 (de) Acetylenderivate
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
CR11452A (es) 5-((3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino)-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiflamatorios
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
GB0602951D0 (en) Organic Compounds
DK1819704T3 (da) Pyrrolopyridin-2-carboxylsyre-amid-derivat anvendelig som inhibitor af glycogenphosphorylase